An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.

Trial Profile

An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms PAZEC
  • Most Recent Events

    • 11 Oct 2016 Status changed from recruiting to completed,according to the results published at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Primary endpoint (Progression free survival at 3 months) has been met,according to the results published at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top